June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Prevalence of Dry Eye and Meibomian Gland Dysfunction and their Associations in a Very Old Population. The Ural Very Old Study
Author Affiliations & Notes
  • Ellina Rakhimova
    Ufa Eye Research Institute, Russian Federation
  • Mukharram Bikbov
    Ufa Eye Research Institute, Russian Federation
  • Gyulli Kazakbaeva
    Ufa Eye Research Institute, Russian Federation
  • Songhomitra Panda-Jonas
    Department of Ophthalmology, Medical Faculty Mannheim, Germany
  • Ildar Ponomarev
    Ufa Eye Research Institute, Russian Federation
  • Jost Jonas
    Department of Ophthalmology, Medical Faculty Mannheim, Germany
  • Footnotes
    Commercial Relationships   Ellina Rakhimova, None; Mukharram Bikbov, None; Gyulli Kazakbaeva, None; Songhomitra Panda-Jonas, None; Ildar Ponomarev, None; Jost Jonas, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 703. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ellina Rakhimova, Mukharram Bikbov, Gyulli Kazakbaeva, Songhomitra Panda-Jonas, Ildar Ponomarev, Jost Jonas; Prevalence of Dry Eye and Meibomian Gland Dysfunction and their Associations in a Very Old Population. The Ural Very Old Study. Invest. Ophthalmol. Vis. Sci. 2021;62(8):703.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Although dry eye disease (DED) and Meibomian gland dysfunction (MGD) are worldwide one of the most common ophthalmological complaints by patients, their prevalence in a very old population has remained unknown so far. We assessed DED and MGD prevalences in a very old population.

Methods : The population-based Ural Very Old Study was conducted in a rural and urban area in Bashkortostan/Russia from 2018 to 2020 and included 1526 (81.1%) participants out of 1882 eligible individuals aged 85+ years. A detailed systemic and ophthalmological examination with Schirmer test and slit-lamp based assessment of the Meibomian glands, and an interview with a questionnaire of >300 questions.

Results : The investigation included 1493 (97.8%) individuals with available information about dry eye. Mean age was 88.3±2.9 years (range: 85-103 years). Schirmer test was ≤5 mm in 160 (34.3%; 95% confidence interval (CI): 31.5, 37.1) eyes. The mean score of dry eye symptoms was 7.52±2.14 (95%CI:7.41,7.63). A MGD grade 1,2,3 and 4 in the worse eye was diagnosed in 367 (31.4%), 309 (26.4%), 89 (7.6%), and 39 (3.3%) eyes, respectively. The prevalence of DED diagnosis 1 (dry eye symptoms score ≥7, Schirmer test <5 mm), 2 (score ≥8, Schirmer test <5 mm), 3 (score ≥9, Schirmer test <5 mm), 4 (score ≥7, Schirmer test ≤5 mm, MGD grade 1 (telangiectasia at the lid margin)), and 5 (score ≥7, Schirmer test ≤5 mm, MGD grade 2 (plugged Meibomian gland orifices) or higher) were 18.2% (95%CI:16.0,20.5), 14.5% (95%CI:12.4,16.5), 8.1% (95%CI:6.5,9.7), 14.8% (95%CI:12.7,16.8), and 7.4% (95%CI:5.9,9.0), respectively. In multivariate analysis, a higher DED prevalence (dry eye symptoms score ≥8;Schirmer test <5mm) was associated with female sex (odds ratio (OR):2.36;95%CI:1.18,4.71;P=0.02),rural region of habitation (OR:2.72;95%CI:1.10,6.70;P=0.03), longer axial length (OR:1.30;95%CI:1.04,1.62;P=0.02), and higher hearing loss score (OR:1.03;95%CI:1.01,1.05;P=0.001) and lower self-reported salt consumption (OR:0.64;95%CI:0.54,0.75;P<0.001).

Conclusions : : In this population-based recruited study sample aged 85+years, DED prevalence (7.4% to 18.2% depending on the definition) and MGD prevalence (31.4%) was associated with female sex, rural region of habitation, longer axial length, higher hearing loss score and lower salt consumption.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×